aTyr Pharma, Inc. (LIFE)
|Net Income (ttm)||-29.07M|
|Day's Range||9.31 - 10.54|
|52-Week Range||2.93 - 12.97|
|Price Target||19.40 (+88.2%)|
|Est. Earnings Date||Nov 11, 2021|
aTyr Pharma, Inc., a clinical stage biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. The company's lead clinical product candidate is ATYR1923, a selective modulator of NRP2 for the treatment of patients with severe inflammatory lung diseases, including interstitial lung diseases (ILDs) and severe respiratory complications caused by COVID-19. Its product, ATYR1923, is in Phase 1b/2a multi-center clinical trial for pulmonary sarcoidosis. The company is also... [Read more...]
In 2020, aTyr Pharma's revenue was $10.46 million, an increase of 2,377.49% compared to the previous year's $422,000. Losses were -$16.22 million, -31.26% less than in 2019.Financial Statements
According to 3 analysts, the average rating for aTyr Pharma stock is "Buy." The 12-month stock price forecast is 19.40, which is an increase of 88.17% from the latest price.
SAN DIEGO, Sept. 16, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathw...
SAN DIEGO, Sept. 15, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a clinical stage biotherapeutics company engaged in the discovery and development of innovative medicines based on novel b...
aTyr Pharma (LIFE) soars following the announcement of positive results from its phase Ib/IIa study of its lead candidate, ATYR1923, for pulmonary sarcoidosis.
Atyr Pharma (LIFE) stock is soaring higher on Tuesday after the company released positive data from a recent clinical trial. The post LIFE Stock: 7 Things to Know About Biotech aTyr Pharma as Shares Soa...
aTyr Pharma Inc (NASDAQ: LIFE) is trading significantly higher Tuesday after multiple analyst firms maintained bullish ratings on the stock and raised their respective price targets following the compan...
H.C. Wainwright increased the price target on ATyr Pharma (NASDAQ:LIFE) to $18 from $13, with the Buy rating unchanged, implying more than 120% upside. Today, the Company reported positive data from a p...
Today, some news of positive clinical trial results for one of aTry's leading drug candidates has sent LIFE stock surging. The post LIFE Stock: What Is the Clinical Trial News Sending aTyr Pharma Soaring?
ATyr Pharma Inc (NASDAQ: LIFE) has announced positive results from its Phase 1b/2a trial evaluating its lead therapeutic candidate, ATYR1923, in pulmonary sarcoidosis, a major form of interstitial lung ...
aTyr Pharma Announces Positive Data from Phase 1b/2a Clinical Trial Demonstrating Consistent Dose Response for ATYR19...
Trial met primary endpoint, ATYR1923 was safe and well-tolerated.
aTyr Pharma and its Hong Kong Subsidiary, Pangu BioPharma, Announce Positive Data from a Phase 1b/2a Clinical Trial D...
Pangu's basic and translational research in tRNA synthetase biology, conducted in collaboration with the Hong Kong University of Science and Technology, contributed to successful clinical proof-of-conce...
Investors need to pay close attention to aTyr Pharma (LIFE) stock based on the movements in the options market lately.
Atyr Pharma (LIFE) delivered earnings and revenue surprises of -39.13% and -100.00%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Shares of aTyr Pharma (NASDAQ:LIFE) fell in after-market trading after the company reported Q2 results. Quarterly Results Earnings per share increased 7.25% over the past year to ($0.64), which missed t...
Data from Phase 1b/2a clinical trial of ATYR1923 in pulmonary sarcoidosis expected in mid-September 2021.
LOS ANGELES--(BUSINESS WIRE)---- $LIFE #CapitalCommitment--Russian listed pharmaceutical manufacturer, Pharmsynthez PJSC (MOEX:LIFE), secures 800 million rubles from global alternative investor, LDA Cap...
aTyr Pharma to Host Virtual Key Opinion Leader Event on Current Treatment Options for Pulmonary Sarcoidosis
Event will feature Dr. Daniel Culver, Director of the Interstitial Lung Disease Program at the Cleveland Clinic.
Preclinical candidate is second to demonstrate selective blocking ability from in-house panel of antibodies targeting NRP2.
Atyr Pharma (LIFE) delivered earnings and revenue surprises of -50.00% and -100.00%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Data from Phase 1b/2a clinical trial of ATYR1923 in pulmonary sarcoidosis expected in the third quarter.
Atyr Pharma (LIFE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
aTyr Pharma and Foundation for Sarcoidosis Research Announce Town Hall Virtual Meeting on Steroids and Sarcoidosis
Panel discussion on steroids and sarcoidosis to be held on Tuesday, April 27 at 12:00pm ET / 3:00pm PT Panel discussion on steroids and sarcoidosis to be held on Tuesday, April 27 at 12:00pm ET / 3:00pm PT
aTyr Pharma Inc (NASDAQ: LIFE) and Lonza Group Ltd (OTCMKTS: LZAGF) have agreed to manufacture ATYR2810, aTyr's monoclonal antibody targeting Neuropilin-2 (NRP2) that is currently in preclinical develop...
aTyr Pharma Presents Preclinical Research Showing Effects of ATYR2810 in Lung and Breast Cancer at the 2021 AACR Virt...
Findings demonstrate tumor inhibitory effects of ATYR2810 when used as a monotherapy or in combination with chemotherapy in models of non-small cell lung cancer.
Shares of aTyr Pharma (NASDAQ:LIFE) rose in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share rose 69.48% over the past year to ($0.47), which beat the est...